Paragon Care (ASX:PGC) Full Year 2024 Results
Key Financial Results
- Revenue: AU$2.97b (up 36% from FY 2023).
- Net income: AU$8.38m (down 35% from FY 2023).
- Profit margin: 0.3% (down from 0.6% in FY 2023).
- EPS: AU$0.009 (down from AU$0.014 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Paragon Care Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 29%.
In the last 12 months, the only revenue segment was Distribution of Pharmaceuticals and Medical Consumables to The Healthcare Market contributing AU$2.97b. Notably, cost of sales worth AU$2.79b amounted to 94% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to AU$85.4m (51% of total expenses). Explore how PGC's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Healthcare industry in Australia.
Performance of the Australian Healthcare industry.
The company's shares are up 8.6% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for Paragon Care that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:PGC
Paragon Care
Distributes medical equipment, devices, and consumables to the healthcare markets in Australia, New Zealand, and Asia.
Reasonable growth potential with adequate balance sheet.
